Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Immunovant, Inc. (IMVT) had Return on Tangible Equity of -31.51% for the most recently reported fiscal quarter, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-111.12M |
|
-- |
|
-- |
|
$114.30M |
|
$-114.30M |
|
$3.33M |
|
$-110.97M |
|
$-110.97M |
|
$-111.12M |
|
$-111.12M |
|
$-111.12M |
|
$-111.12M |
|
$-114.30M |
|
$-114.20M |
|
146.92M |
|
146.92M |
|
$-0.76 |
|
$-0.76 |
|
| Balance Sheet Financials | |
$412.54M |
|
$0.75M |
|
$8.39M |
|
$420.93M |
|
$68.31M |
|
-- |
|
-- |
|
$68.31M |
|
$352.62M |
|
$352.62M |
|
$352.62M |
|
147.20M |
|
| Cash Flow Statement Financials | |
$-265.24M |
|
$-0.56M |
|
$3.88M |
|
$635.37M |
|
$374.69M |
|
$-260.68M |
|
$37.80M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
6.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-265.80M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-31.51% |
|
|
Return on Tangible Equity |
-31.51% |
-26.40% |
|
-31.51% |
|
$2.40 |
|
$-1.81 |
|
$-1.81 |
|